Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Chronic kidney disease (CKD) has become one of the most frequent non-infectious comorbidities in the aging HIV-infected population on long-standing combination antiretroviral therapy (cART).

Methods

We conducted a retrospective, cross-sectional study including HIV-infected adult patients attending our HIV outpatient clinic during the years 2017 and 2018 to assess prevalence and associated risk factors of CKD. Estimated glomerular filtration rate (eGFR) was measured by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. CKD was diagnosed and classified according to the National Kidney Foundation guidelines. Logistic regression was employed to identify factors associated with CKD.

Results

We enrolled 2339 HIV-infected patients (91% were Caucasian) with a mean age of 45.3 years and a mean current CD4 lymphocyte count of 531 cells/mm3. CKD was diagnosed in 311 subjects (13.3%). Overall, 294 (12.6%) patients had albuminuria, 108 (4.6%) had eGFR < 60 mL/min/1.73 m2, and 78 (3.3%) had albuminuria plus eGFR < 60 mL/min/1.73 m2. Stages 4–5 of CKD were documented in 23 (1%) cases. Age greater than 50 years, male gender, hypertension, diabetes mellitus, high triglycerides, nadir CD4 cell count < 200 cells/mm3, current use of tenofovir disoproxyl fumarate (TDF) and of TDF plus a ritonavir-boosted protease inhibitors were independently associated with CKD, while current use of abacavir plus one integrase inhibitor was associated with a reduced risk of CKD.

Conclusion

There is a significant prevalence of CKD among HIV-infected persons in association with both traditional and HIV-specific risk factors, requiring a careful periodic monitoring of renal function in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collaboration Antiretroviral Therapy Cohort. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356356.

    Article  Google Scholar 

  2. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ekrikpo U, Kengne A, Bello A, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One. 2018;13:e0195443.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kooij KW, Vogt L, Wit FW, et al. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis. 2017;216:622–31.

    Article  CAS  PubMed  Google Scholar 

  5. Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV. 2015;2:e288–e298298.

    Article  PubMed  Google Scholar 

  6. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–7.

    Article  CAS  PubMed  Google Scholar 

  7. Hamzah L, Jose S, Booth JW, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J Infect. 2017;74:492–500.

    Article  CAS  PubMed  Google Scholar 

  8. Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3:e23–32.

    Article  PubMed  Google Scholar 

  9. Ryom L, Mocroft A, Kirk O, et al. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017;31:1261–70.

    Article  PubMed  Google Scholar 

  10. Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4:388–95.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bruggeman LA, Bark C, Kalayjan RC. HIV and the kidney. Curr Infect Dis Rep. 2009;11:479–85.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.

    Google Scholar 

  14. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis. 2005;40:1559–855.

    Article  PubMed  Google Scholar 

  15. Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group. KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.

    Google Scholar 

  16. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guidelines for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96–138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Halle MP, Oumarou M, Kaze Folefack F, Mapoure Y, Mbatchou Ngahane BH, Luma Namme H. Prevalence and associated factors of chronic kidney disease among patients infected with human immunodeficiency virus in Cameroon. Iran J Kidney Dis. 2018;12:268–74.

    Google Scholar 

  18. Yanagisawa N, Muramatsu T, Koibuchi T et al (2018) Prevalence of chronic kidney disease and poor diagnostic accuracy of dipstick proteinuria in human immunodeficiency virus-infected individuals: a multicenter study in Japan. Open Forum Infect Dis 5:ofy216

  19. Juega-Marino J, Bonjoch A, Perez-Alvarez N, et al. Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. Medicine (Baltimore). 2017;96:e7421.

    Article  Google Scholar 

  20. Calza L, Vanino E, Magistrelli E, et al. Prevalence of renal disease within an urban HIV-infected cohort in Northern Italy. Clin Exp Nephrol. 2014;18:104–12.

    Article  PubMed  Google Scholar 

  21. Sutton SS, Magagnoli J, Cummings TH, Hardin JW, Edun B, Beaubrun A (2018) Chronic kidney disease, cardiovascular disease, and osteoporotic fractures in patients with and without HIV in the US Veteran’s Affairs Administration System. Curr Med Res Opin (Epub ahead of print)

  22. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–788.

    Article  CAS  PubMed  Google Scholar 

  23. Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75:211–8.

    Article  CAS  PubMed  Google Scholar 

  24. Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75:226–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Achhra AC, Nugent M, Mocroft A, Ryom L, Wyatt CM. Chronic kidney disease and antiretroviral therapy in HIV-positive individuals: recent developments. Curr HIV/AIDS Rep. 2016;13:149–57.

    Article  PubMed  Google Scholar 

  26. Hamzah L, Jones R, Post FA. Optimizing antiretroviral regimens in chronic kidney disease. Curr Opin Infect Dis. 2019;32:1–7.

    Article  CAS  PubMed  Google Scholar 

  27. Maggi P, Montinaro V, Mussini C, et al. Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Rev. 2014;16:144–51.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, “Alma Mater Studiorum” University of Bologna, via G. Massarenti 11, 40138, Bologna, Italy

    Leonardo Calza, Michele Sachs, Vincenzo Colangeli, Marco Borderi, Bianca Granozzi, Pietro Malosso & Pierluigi Viale

  2. Unit of Nephrology, Department of Medical and Surgical Sciences, S.Orsola Hospital, University of Bologna, Bologna, Italy

    Giorgia Comai, Valeria Corradetti & Gaetano La Manna

Authors
  1. Leonardo Calza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Sachs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincenzo Colangeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Borderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bianca Granozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pietro Malosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorgia Comai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Valeria Corradetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gaetano La Manna
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierluigi Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonardo Calza.

Ethics declarations

Conflicts of interest

There are no conflicts of interest.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board at the S.Orsola-Malpighi Hospital approval (approval number: 198/2017/O/Oss).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Calza, L., Sachs, M., Colangeli, V. et al. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy. Clin Exp Nephrol 23, 1272–1279 (2019). https://doi.org/10.1007/s10157-019-01768-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-019-01768-9

Keywords

Search

Navigation